Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant Melanoma Registry

Leiter, Ulrike; Buettner, Petra G.; Eigentler, Thomas; Bröcker, Eva B.; Voit, Christiane; Gollnick, Harald; Marsch, Wolfgang Ch.; Wollina, Uwe; Meier, Friedegund; Garbe, Claus

doi:10.1016/j.jaad.2010.09.772

Cited by 86 publications

(92 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The costs of excising benign suspicious lesions included the surgery and pathology costs. Transition probabilities (TPs) associated to blue and orange arrows were estimated using the data from, respectively, Leiter et al [10] and Eggermont et al [11]. TPs to death from any cause (green arrows) were obtained from the Belgian mortality tables [13].…”

Section: Costsmentioning

confidence: 99%

“…Our model therefore differs from the classical 'Markov models' often used for CEA, for which TPs are assumed to be time independent [10]. The TPs were based on the data presented in Leiter et al [11], Eggermont et al [12] and Maio et al [13]. For this CEA, contrary to the MDM presented previously [2], we consider that patients can die from any cause at any age (versus only at the end of life expectancy in the previous analysis).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy

Tromme

Legrand

Devleesschauwer

et al. 2016

European Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Aim: The main aim of this study is to demonstrate how our melanoma disease model (MDM) can be used for cost-effectiveness analyses (CEAs) in the melanoma detection field. In particular, we used the data of two cohorts of Belgian melanoma patients to investigate the cost-effectiveness of dermoscopy. Methods: A MDM, previously constructed to calculate the melanoma burden, was slightly modified to be suitable for CEAs. Two cohorts of patients entered into the model to calculate morbidity, mortality and costs. These cohorts were constituted by melanoma patients diagnosed by dermatologists adequately, or not adequately, trained in dermoscopy. Effectiveness and costs were calculated for each cohort and compared. Effectiveness was expressed in (2016) 38e45 quality-adjusted life years (QALYs), a composite measure depending on melanoma-related morbidity and mortality. Costs included costs of treatment and follow-up as well as costs of detection in non-melanoma patients and costs of excision and pathology of benign lesions excised to rule out melanoma. Results: The result of our analysis concluded that melanoma diagnosis by dermatologists adequately trained in dermoscopy resulted in both a gain of QALYs (less morbidity and/or mortality) and a reduction in costs. Conclusion: This study demonstrates how our MDM can be used in CEAs in the melanoma detection field. The model and the methodology suggested in this paper were applied to two cohorts of Belgian melanoma patients. Their analysis concluded that adequate dermoscopy training is cost-effective. The results should be confirmed by a large-scale randomised study. ª

show abstract

Section: Costsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy

Tromme

Legrand

Devleesschauwer

et al. 2016

European Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Prognostic factors of the primary tumor appear to no longer exert any influence on recurrence risk after a period of more than 8 years. Approximation of recurrence rates at a low level of < 1 : 30 people per month and year sets in after about 10 years, making recurrences increasingly less likely after that time [300,591,600]. This data suggests discontinuation of follow-up after 10 years.…”

Section: Background Information On the Clinical Decision Processmentioning

confidence: 87%

“…Stage IA showed consistently low hazard rates during the entire follow-up period of 10 years. After a period of 10 years, hazard rates at stages IB-III converge with stage IA rates [300].…”

Section: Background Information On the Clinical Decision Processmentioning

confidence: 98%